Grace Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 40.81M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The co...